Additional Study Information: This is the first research study of LYT-200 in people and the main purpose of this study is to test the safety and tolerability of LYT-200. LYT-200 is intended to inhibit (hinder) galectin 9. Galectin 9 is a protein which suppresses immune function and disables the immune systems attack on cancer through multiple ways. In this study, we shall also examine how the drug is changed by and removed from the body and will look for signs that the drug may be truly effective against cancer. Cancers include: Colon cancer, rectal cancer, liver cancer, lung cancer, and pancreatic cancer.